BE of Torrent's Esomeprazole Mg DR Capsules
NCT02680119 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56
Last updated 2016-02-11
Summary
Subjects to compare the single dose bioavailability of Torrent's Esomeprazole Mg DR Capsule 1×40 mg and Nexium 40 mg DR Capsule containing Esomeprazole 40 mg of AastraZeneca LP, USA. Dosing periods of studies were separated by a washout period of 5 days.
Conditions
- Healthy
Interventions
- DRUG
-
Nexium 40 mg DR Capsules of AstraZeneca LP, USA.
oral, crossover
- DRUG
-
Torrent's Esomeprazole Magnesium DR Capsules 40 mg
oral, crossover
Sponsors & Collaborators
-
Torrent Pharmaceuticals Limited
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2011-05-31
- Primary Completion
- 2011-05-31
- Completion
- 2011-05-31
More Related Trials
-
An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
NCT00629564 ·Status: COMPLETED ·Phase: PHASE4
-
Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
NCT00625495 ·Status: COMPLETED ·Phase: PHASE4
-
Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv
NCT00626262 ·Status: COMPLETED ·Phase: PHASE4
-
Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously
NCT00635414 ·Status: COMPLETED ·Phase: PHASE4
-
Drug Interaction Study Between AZD3355 and Nexium
NCT00684190 ·Status: COMPLETED ·Phase: PHASE1
-
Esomeprazole Bioavailability Study With 40 mg Oral Single Dose Fasted and Fed Administration
NCT00889850 ·Status: COMPLETED ·Phase: PHASE1
-
Acid-Associated Heartburn Symptoms and Dose of Esomeprazole
NCT00206024 ·Status: COMPLETED ·Phase: PHASE4
-
Bioequivalence Study of Esomeprazole in Healthy Adult Subjects Under Fasting Condition
NCT05235217 ·Status: COMPLETED ·Phase: PHASE1
-
Prevention of Gastric Ulcers
NCT00629512 ·Status: COMPLETED ·Phase: PHASE3
-
Ulcer Prevention II
NCT00629928 ·Status: COMPLETED ·Phase: PHASE3
-
Nexium RESPONSE Trial
NCT00318968 ·Status: COMPLETED ·Phase: PHASE4
-
A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD)
NCT00626535 ·Status: COMPLETED ·Phase: PHASE3
-
Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs
NCT00241540 ·Status: COMPLETED ·Phase: PHASE3
-
Study Comparing a Fixed-Dose Capsule of Esomeprazole 40mg and LDA 325mg With Free Combination
NCT00688428 ·Status: COMPLETED ·Phase: PHASE1
-
NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis
NCT00206180 ·Status: COMPLETED ·Phase: PHASE4
-
A Pharmacokinetic Study to Evaluate the Bioequivalence of a Test Formulation Compared to an Equivalent Dose of a Reference Drug Product
NCT02444507 ·Status: UNKNOWN ·Phase: PHASE4
-
An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium
NCT00428701 ·Status: COMPLETED ·Phase: PHASE4
-
Esomeprazole And Symptomatic Response In Patients With Or Without An Elevated Risk For Non-Steroidal Anti-Inflammatory Drug (NSAID)-Associated GI Damage
NCT00524329 ·Status: COMPLETED
-
Bioequivalence of Two Formulations of Esomeprazole
NCT02543606 ·Status: COMPLETED ·Phase: PHASE4
-
A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.
NCT00206284 ·Status: COMPLETED ·Phase: PHASE2
-
Nexium Dyspepsia/AST
NCT00251914 ·Status: COMPLETED ·Phase: PHASE3
-
Nexium Dyspepsia/AST
NCT00251992 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)
NCT00242736 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma
NCT00317044 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetic Study of Esomeprazole Magnesium in Patients 1 to 11 Years-Old With Endoscopically-Proven Gastroesophageal Reflux Disease (GERD)
NCT00687245 ·Status: COMPLETED ·Phase: PHASE1